Logo image of CLDX

CELLDEX THERAPEUTICS INC (CLDX) Stock Fundamental Analysis

USA - NASDAQ:CLDX - US15117B2025 - Common Stock

25.15 USD
+0.69 (+2.82%)
Last: 9/18/2025, 11:25:41 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CLDX. CLDX was compared to 540 industry peers in the Biotechnology industry. CLDX has a great financial health rating, but its profitability evaluates not so good. CLDX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLDX had negative earnings in the past year.
CLDX had a negative operating cash flow in the past year.
CLDX had negative earnings in each of the past 5 years.
In the past 5 years CLDX always reported negative operating cash flow.
CLDX Yearly Net Income VS EBIT VS OCF VS FCFCLDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CLDX has a Return On Assets of -28.83%. This is in the better half of the industry: CLDX outperforms 67.96% of its industry peers.
CLDX has a better Return On Equity (-30.46%) than 77.04% of its industry peers.
Industry RankSector Rank
ROA -28.83%
ROE -30.46%
ROIC N/A
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
CLDX Yearly ROA, ROE, ROICCLDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CLDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDX Yearly Profit, Operating, Gross MarginsCLDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLDX has been increased compared to 5 years ago.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLDX Yearly Shares OutstandingCLDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLDX Yearly Total Debt VS Total AssetsCLDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CLDX has an Altman-Z score of 22.93. This indicates that CLDX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CLDX (22.93) is better than 93.52% of its industry peers.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.93
ROIC/WACCN/A
WACC9.55%
CLDX Yearly LT Debt VS Equity VS FCFCLDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CLDX has a Current Ratio of 19.67. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 19.67, CLDX belongs to the best of the industry, outperforming 93.70% of the companies in the same industry.
A Quick Ratio of 19.67 indicates that CLDX has no problem at all paying its short term obligations.
CLDX has a Quick ratio of 19.67. This is amongst the best in the industry. CLDX outperforms 93.70% of its industry peers.
Industry RankSector Rank
Current Ratio 19.67
Quick Ratio 19.67
CLDX Yearly Current Assets VS Current LiabilitesCLDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CLDX have decreased by -9.85% in the last year.
The Revenue for CLDX has decreased by -30.27% in the past year. This is quite bad
CLDX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.48% yearly.
EPS 1Y (TTM)-9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
Revenue 1Y (TTM)-30.27%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-70.78%

3.2 Future

Based on estimates for the next years, CLDX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.49% on average per year.
CLDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 153.17% yearly.
EPS Next Y-44.69%
EPS Next 2Y-31.13%
EPS Next 3Y-18.54%
EPS Next 5Y20.49%
Revenue Next Year-46.09%
Revenue Next 2Y-30.03%
Revenue Next 3Y63.67%
Revenue Next 5Y153.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLDX Yearly Revenue VS EstimatesCLDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
CLDX Yearly EPS VS EstimatesCLDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDX Price Earnings VS Forward Price EarningsCLDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDX Per share dataCLDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

CLDX's earnings are expected to decrease with -18.54% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.13%
EPS Next 3Y-18.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLDEX THERAPEUTICS INC

NASDAQ:CLDX (9/18/2025, 11:25:41 AM)

25.15

+0.69 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04
Inst Owners113.17%
Inst Owner Change-6.9%
Ins Owners0.21%
Ins Owner Change-0.08%
Market Cap1.67B
Analysts83.81
Price Target57.38 (128.15%)
Short Float %10.89%
Short Ratio5.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.28%
Min EPS beat(2)-5.18%
Max EPS beat(2)2.62%
EPS beat(4)3
Avg EPS beat(4)2.34%
Min EPS beat(4)-5.18%
Max EPS beat(4)6.71%
EPS beat(8)5
Avg EPS beat(8)1.72%
EPS beat(12)9
Avg EPS beat(12)2.67%
EPS beat(16)9
Avg EPS beat(16)-0.68%
Revenue beat(2)0
Avg Revenue beat(2)-31.89%
Min Revenue beat(2)-34.86%
Max Revenue beat(2)-28.92%
Revenue beat(4)2
Avg Revenue beat(4)54.29%
Min Revenue beat(4)-34.86%
Max Revenue beat(4)277.69%
Revenue beat(8)5
Avg Revenue beat(8)108.94%
Revenue beat(12)8
Avg Revenue beat(12)121.84%
Revenue beat(16)8
Avg Revenue beat(16)73.39%
PT rev (1m)-3.98%
PT rev (3m)-1.75%
EPS NQ rev (1m)-0.48%
EPS NQ rev (3m)-4.37%
EPS NY rev (1m)-0.67%
EPS NY rev (3m)-1.4%
Revenue NQ rev (1m)-4.01%
Revenue NQ rev (3m)79.97%
Revenue NY rev (1m)-5.08%
Revenue NY rev (3m)-5.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 288.42
P/FCF N/A
P/OCF N/A
P/B 2.55
P/tB 2.66
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)-4.21
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.8
OCFYN/A
SpS0.09
BVpS9.87
TBVpS9.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.83%
ROE -30.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.58%
Cap/Sales 39.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.67
Quick Ratio 19.67
Altman-Z 22.93
F-Score2
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)61.32%
Cap/Depr(5y)52.82%
Cap/Sales(3y)43.76%
Cap/Sales(5y)35.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.41%
EPS Next Y-44.69%
EPS Next 2Y-31.13%
EPS Next 3Y-18.54%
EPS Next 5Y20.49%
Revenue 1Y (TTM)-30.27%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-70.78%
Revenue Next Year-46.09%
Revenue Next 2Y-30.03%
Revenue Next 3Y63.67%
Revenue Next 5Y153.17%
EBIT growth 1Y-43.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.37%
EBIT Next 3Y-16.14%
EBIT Next 5YN/A
FCF growth 1Y-64.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.18%
OCF growth 3YN/A
OCF growth 5YN/A